Interpace Biosciences' Q4 revenue falls 26% after PancraGEN discontinuation

Interpace Biosciences

30/03/2026 21:10

Overview

US thyroid diagnostics firm's Q4 revenue declined 26% yr/yr, reflecting PancraGEN discontinuation

Q4 net income from continuing operations benefited from a one-time, non-cash tax-related accounting adjustment

Q4 thyroid test volume and thyroid revenue both increased yr/yr

Outlook

Interpace expects approximately 16% yr-over-yr thyroid revenue growth in 2026

Company aims to scale thyroid test volume through deeper adoption and account growth

Interpace targets productivity gains via automation and operational discipline in 2026

Result Drivers

TAX-RELATED ADJUSTMENT - Q4 net income from cont. ops. was significantly boosted by a one-time, non-cash tax-related accounting adjustment related to the release of a deferred tax valuation allowance

THYROID TEST GROWTH - Q4 thyroid test volume increased 11% and thyroid revenue rose 14% yr/yr, reflecting growth in the core thyroid diagnostics business

Company press release: ID:nGNX4VLKMR

Key Details

Metric
Beat/Miss
Actual
Consensus Estimate
Q4 Revenue
$9.22 mln
Q4 Net Income
$22.66 mln
Q4 Gross Profit
$6.04 mln
Q4 Operating Expenses
$4.47 mln
Q4 Operating Income
$1.58 mln


For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact reuters.support@thomsonreuters.com.

(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)